A guide to understanding clinical trial design, endpoints, statistical significance, and how to critically evaluate peptide research studies.
Filed under evidence research, written for beginner, patient-consumer, researcher, journalist.
Not medically reviewed. Last updated 2026-03-20. Nothing here is medical advice.
Clinical trials are the gold standard for evaluating whether a peptide is safe and effective. Understanding how to read and interpret trial data is essential for anyone evaluating peptide evidence.
Evidence quality varies by study type:
1. **Systematic reviews and meta-analyses** — highest level
2. **Randomized controlled trials (RCTs)** — gold standard for individual studies
3. **Cohort studies** — observational, may show associations
4. **Case reports and series** — weakest clinical evidence
5. **In vitro and animal studies** — not directly applicable to humans
Larger trials generally produce more reliable results. A peptide tested in 20 people provides much weaker evidence than one tested in 2,000.
Double-blind, placebo-controlled trials minimize bias. Open-label studies or uncontrolled trials are more prone to placebo effects and observer bias.
The primary endpoint is the main outcome the trial was designed to measure. Secondary endpoints are additional observations. Results should be interpreted in context of which endpoints were pre-specified.
A p-value below 0.05 is conventionally considered statistically significant, but clinical significance matters more. A statistically significant but tiny effect may not be clinically meaningful.
Note who funded the study and whether authors have financial relationships with the peptide's manufacturer.
This guide is intended to support research literacy, not to provide treatment recommendations.
More guides: All guides, Safety centre, Peptide library.